NO20082297L - Piperazinderivater som er anvendelige som CCR5-antagonister - Google Patents

Piperazinderivater som er anvendelige som CCR5-antagonister

Info

Publication number
NO20082297L
NO20082297L NO20082297A NO20082297A NO20082297L NO 20082297 L NO20082297 L NO 20082297L NO 20082297 A NO20082297 A NO 20082297A NO 20082297 A NO20082297 A NO 20082297A NO 20082297 L NO20082297 L NO 20082297L
Authority
NO
Norway
Prior art keywords
ccr5 antagonists
derivatives useful
piperazine derivatives
arthritis
ccr5
Prior art date
Application number
NO20082297A
Other languages
English (en)
Norwegian (no)
Inventor
Anima Ghosal
Swapan K Chowdhury
Kevin B Alton
Michael W Miller
Ragulan Ramanathan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20082297L publication Critical patent/NO20082297L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20082297A 2005-10-21 2008-05-20 Piperazinderivater som er anvendelige som CCR5-antagonister NO20082297L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/255,643 US7825121B2 (en) 1999-05-04 2005-10-21 Piperazine derivatives useful as CCR5 antagonists
PCT/US2006/040636 WO2007050375A2 (en) 2005-10-21 2006-10-18 Piperazine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
NO20082297L true NO20082297L (no) 2008-07-21

Family

ID=37872167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082297A NO20082297L (no) 2005-10-21 2008-05-20 Piperazinderivater som er anvendelige som CCR5-antagonister

Country Status (17)

Country Link
US (1) US7825121B2 (pt)
EP (1) EP1951708B1 (pt)
JP (2) JP2009512705A (pt)
KR (1) KR20080058486A (pt)
CN (1) CN101326178A (pt)
AR (1) AR058105A1 (pt)
AU (1) AU2006306491B2 (pt)
BR (1) BRPI0617731A2 (pt)
CA (1) CA2626565A1 (pt)
EC (1) ECSP088378A (pt)
IL (1) IL190902A0 (pt)
NO (1) NO20082297L (pt)
PE (1) PE20070711A1 (pt)
RU (1) RU2008119652A (pt)
TW (1) TW200800234A (pt)
WO (1) WO2007050375A2 (pt)
ZA (1) ZA200803454B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005234596B8 (en) * 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
SI1954697T1 (sl) * 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
GB201118876D0 (en) 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP2861302A4 (en) 2012-05-14 2016-08-24 Prostagene Llc USE OF CCR5 MODULATORS FOR THE TREATMENT OF CANCER
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
US12459808B2 (en) 2021-09-13 2025-11-04 Kabushiki Kaisha Toshiba Sensor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103214T2 (tr) * 1999-05-04 2002-03-21 Schering Corporation CCR5 antagonistleri olarak yararlì piperazin trevleri.
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
HUP0400389A3 (en) 2001-03-29 2008-03-28 Schering Corp Aryl oxime-piperazines useful as ccr5 antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2626565A1 (en) 2007-05-03
RU2008119652A (ru) 2009-11-27
AU2006306491B2 (en) 2012-12-13
PE20070711A1 (es) 2007-08-11
WO2007050375A2 (en) 2007-05-03
US20060105964A1 (en) 2006-05-18
BRPI0617731A2 (pt) 2011-08-02
EP1951708B1 (en) 2013-11-20
JP2012072195A (ja) 2012-04-12
AR058105A1 (es) 2008-01-23
US7825121B2 (en) 2010-11-02
KR20080058486A (ko) 2008-06-25
ZA200803454B (en) 2009-04-29
AU2006306491A1 (en) 2007-05-03
JP2009512705A (ja) 2009-03-26
IL190902A0 (en) 2008-11-03
TW200800234A (en) 2008-01-01
EP1951708A2 (en) 2008-08-06
ECSP088378A (es) 2008-05-30
WO2007050375A3 (en) 2007-06-14
CN101326178A (zh) 2008-12-17

Similar Documents

Publication Publication Date Title
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
WO2006021378A8 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
NO20070484L (no) Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer.
NO20071593L (no) Pyrimidinderivater
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
NO20080125L (no) 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
ME01515B (me) PIRIMIDINSKI DERIVATI ZA TRETMAN ASTME, HOBP, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUNKTIVITISA, ATOPIČNOG DERMATITISA, RAKA, HEPATITISA B, HEPATITISA C, HIV-a, HPV-a, BAKTERIJSKIH INFEKCIJA I DERMATOZE
NO20066055L (no) Pyridinderivater
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
NO20083642L (no) Dibenzylaminderivater som CETP-inhibitorer
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
MX2010003849A (es) Antagonistas de cgrp.
TW200606581A (en) A chemically amplified positive resist composition, a haloester derivative and a process for producing the same
WO2007036532A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
SG163540A1 (en) Substituted glycinamides having an antithrombotic and factor xa- inhibiting effect
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ECSP088378A (es) Derivados de piperazina útiles como antagonistas de ccr5
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application